NCT07003022View on ClinicalTrials.gov

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2028

Conditions
Colo-rectal CancerMSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Interventions
DRUG

cadonilimab combined with an anti-angiogenic agent, which is selected by the investigator from bevacizumab, regorafenib, or fruquintinib.

Cadonilimab: 10mg/kg Q3W; Bevacizumab: 7.5mg/kg Q3W; Regorafenib: 80mg QD; Fruquintinib: 3mg QD.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT07003022 - Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC | Biotech Hunter | Biotech Hunter